The target of rapamycin (TOR) is an evolutionarily conserved protein kinase that regulates cell growth in response to various environmental as well as intracellular cues through the formation of 2 distinct TOR complexes (TORC), TORC1 and TORC2. Dysregulation of TORC1 and TORC2 activity is closely associated with various diseases, including diabetes, cancer and neurodegenerative disorders. Over the past few years, new regulatory mechanisms of TORC1 and TORC2 activity have been elucidated. Furthermore, recent advances in the study of TOR inhibitors have revealed previously unrecognized cellular functions of TORC1. In this review, we briefly summarize the current understanding of the evolutionarily conserved TOR signalling from upstream regulators to downstream events.
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The Structure and Complex Formation of TOR
The target of rapamycin (TOR) was originally identified as the cellular target of the immunosuppressant and anti-cancer drug rapamycin. TOR is a conserved serine/threonine kinase that belongs to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, which includes ATR, ATM and DNA-PKcs. Structurally, TOR possesses HEAT repeats at the N-terminal region and the FAT, kinase catalytic and FATC domains at the C-terminal region (Fig. 1A) . Rapamycin, together with its cellular receptor 12-kDa FK506-binding protein (FKBP12), binds to the FKBP12-rapamycin binding (FRB) domain located between the FAT and kinase catalytic domains on TOR and thus allosterically inhibits the activity of TOR (1) (Fig. 1A ). The precise mechanism of this inhibition remains unclear.
TOR exerts its function by forming two functionally and structurally distinct complexes, called TOR complex 1 (TORC1) and TORC2. Mammalian TORC1 (mTORC1) comprises of mammalian (or mechanistic) TOR (mTOR), the regulatory-associated protein of mTOR (Raptor), mammalian LST8 (mLst8, also known as GbL), the DEP domain-containing mTOR-interacting protein (Deptor), and proline-rich Akt substrate of 40-kDa (PRAS40). On the other hand, mTORC2 contains mTOR, the rapamycin-insensitive companion of mTOR (Rictor), mLst8, mSin1, Deptor and protein observed with Rictor 1 and 2 (Protor1/2) ( Fig. 1B) . Both mTORC1 and mTORC2, and most likely TORC1 and TORC2 in general, function as multimers (1) . The structural components of both these TORCs are highly conserved from yeast to mammals (Table I) . A prominent difference between these two complexes is their rapamycin sensitivity. TORC1 is sensitive to rapamycin treatment, whereas TORC2 is resistant to rapamycin treatment (1). However, mTORC2 is sensitive to long-term (424 h) rapamycin treatment, and this sensitivity is most likely achieved through inhibition of nascent mTOR molecules from assembling with mTORC2 components such as Rictor and mSin1 (2) . The rapamycin sensitivity of mTORC2 is cell-type dependent, and the factors that bring about this difference are unknown.
Although it was believed that rapamycin inhibits TORC1 activity completely, development of newer ATP-competitive mTOR inhibitors (Torin1, Ku-0063794, PP242 etc.), which inhibit mTOR kinase activity by competing with ATP for binding to the kinase catalytic site ( Fig. 1A) , revealed that rapamycin only partially inhibits mTORC1 activity (3). In fact, even the phosphorylation status of eIF4E-binding protein 1 (4E-BP1), one of the best-characterized substrates of mTORC1, is refractory to inhibition by rapamycin, but is sensitive to the ATP-competitive inhibitors of mTOR, indicating that mTORC1 regulates far more events than previously believed (3) . Discovery of the two TOR complexes (TORC) and rapamycin-insensitive TORC1 activity expands the list of known cellular functions of TOR.
Regulation of TORC1 Activity
Multiple inputs such as nutrients, energy, growth factors and stress converge on TORC1 to coordinately regulate cellular responses to these environmental cues (1, 4) ( Fig. 2 ). Among these, nutrients, especially amino acids (or nitrogen source for yeast), are the most fundamental inputs affecting TORC1 activity throughout evolution. In multicellular organisms, growth factors further fine-tune the regulation of TORC1 activity to achieve appropriate activation status according to the demand of cell growth and overall body growth.
The mechanism of how growth factors (e.g. insulin) signal mTORC1 regulation has been studied extensively. There are at least two mechanisms leading to activation of mTORC1: the tuberous sclerosis complex (TSC)-dependent and TSC-independent pathways (4). TSC1 (also known as hamartin) and TSC2 (also known as tuberin) are gene products whose inactivation causes tuberous sclerosis. The TSC1/TSC2 complex acts as a GTPase activating protein (GAP) for the small GTPase Rheb (1, 4) . The active GTP-bound Rheb directly binds to mTORC1 and enhances its kinase activity. Rheb also acts as a scaffold and mediates the binding of mTORC1 to its substrates (5) . Stimulation by growth factors such as insulin leads to activation of the PI3K-Akt pathway, and then activated Akt phosphorylates and inhibits the GAP activity of TSC2, leading to activation of Rheb. Akt phosphorylation of TSC2 also causes sequestration of TSC2 through binding to 14-3-3 protein. In the TSC1/2-independent pathway of mTORC1 activation, upon stimulation by growth factors, Akt phosphorylates and inactivates PRAS40, the inhibitory component of mTORC1, leading to mTORC1 activation (6) . Amino acids (especially leucine) or nitrogen sources are essential activators of the TORC1 pathway throughout evolution. However, how this amino acid signal activates TORC1 was a long-standing mystery in the TOR field. Over the past few years, there have been considerable advances in our understanding of the amino acid-induced activation of mTORC1. The identification of Rag, a family of small GTPases, was a great step towards understanding regulation of mTORC1 activation by the amino acids (7) . The Rag GTPase family consists of four proteins Rag A, B, C and D. They have a unique property, in that they function as heterodimers composed of two highly similar groups of proteins: RagA or RagB forms heterodimers with either RagC or RagD. Activation of mTORC1 by amino acids is regulated by GTPGDP exchange of these proteins in a reciprocal manner (Fig. 2) . The presence of amino acids leads to heterodimer formation between GTP-bound RagA/B and GDP-bound RagC/D, whereas deprivation of amino acids results in the formation of GDP-bound RagA/B and GTPbound RagC/D (7) . Rag GTPases localize to the surface of the lysosome through association with a heteropenta protein complex called Ragulator (8) . The essential role of the Rag GTPases is to recruit mTORC1 to the surface of lysosome through their ability to bind to Raptor when they are in the activated heterodimer form, i.e. GTP-bound RagA/B-GDPbound RagC/D (Fig. 2 ). Upon being recruited to the surface of the lysosome, mTORC1 is proposed to be activated by association with Rheb that resides on the lysosome (7) . Thus, amino acid signalling mainly operates through the spatial regulation of mTORC1 in Overview of conserved TOR signalling the cells. The importance of Rag GTPases in the TORC1 activation in response to amino acids seems essentially conserved throughout evolution (9, 10), although the amino acid-dependent redistribution of yeast TORC1 has not been observed.
Recent reports by several groups suggest that multiple factors and pathways participate in the amino acid-induced activation of Rag GTPases. Sabatini's group proposed that the amino acid content inside the lysosome is the primary stimulus for activation of mTORC1 (11) . In this scenario, the amino acids present in the lumen of the lysosome regulate the association between Rags and Ragulator through an undefined mechanism involving the activity of vacuolar H þ -ATPase (v-ATPase), and Ragulator acts as a guanine nucleotide exchange factor (GEF) for RagA and RagB, leading to activation of Rag heterodimers (Fig. 2 ). Recent results from both Kim's (in mammalian cells) and Virgilio's (in yeast) groups suggest an amino acid sensing mechanism in the cytoplasm through direct recognition of leucine by leucyl-tRNA synthetase (LRS) (12, 13) ( Fig. 2 ). Mammalian LRS when bound to leucine specifically acts as GAP for RagD, leading to GTP-to-GDP transition of RagD and subsequent mTORC1 activation. In yeast, LRS together with leucine binds to Gtr1, which is the ortholog of mammalian RagA/B, leading to activation of TORC1 through an unknown mechanism. Furthermore, leucine and glutamine are also reported to activate mTORC1 through glutaminolysis (14) . Glutaminolysis converts glutamine to a-ketogluatrate (a-KG) through two sequential steps, where leucine acts as an allosteric activator in the second step. Elevated a-KG level leads to activation of mTORC1 by enhancing GDP-to-GTP transition of RagB, although the precise mechanism remains unknown. Recent reports have further revealed that SH3-domain binding protein 4 (SH3BP4) acts as an inhibitor of Rag GTPases-mTORC1 association in an amino acid-dependent manner (15) . Amino acids promote dissociation of SH3BP4 from Rag GTPases, which allows subsequent binding of mTORC1 to Rag GTPases and mTORC1 activation. In addition, MAP4K3 also appears to act upstream of Rag GTPases in the amino acid sensing pathway (16) .
Although amino acid sensing through the Rag GTPase-mTORC1 axis is a key regulatory mechanism in the mTORC1 pathway not only in cultured cells but also in the physiological setting (17) , another pathway seems to activate mTORC1 in response to amino acids. It is known that human vacuolar protein sorting 34 homologue (hVps34), a class III PI3K, mediates amino acid signalling through mTORC1 (18) . Amino acid stimulation elevates intracellular Ca 2þ levels, which is recognized by calmodulin (CaM). Ca 2þbound CaM binds to hVps34, which in turn directly binds to mTORC1 (Fig. 2) . Consistent with this finding, a recent study also demonstrated that increase of intracellular Ca 2þ level during physical overload activates mTORC1 and promotes protein synthesis, leading to skeletal muscle hypertrophy (19) . mTORC1 activation by hVps34 requires phosphatidylinositol 3-phosphate (PI3P), the lipid product of hVps34.
Interestingly, phospholipase D1 (PLD1) is an effector of PI3P generated by hVps34 (20) , and has been reported to mediate Rheb action towards mTORC1 (21) . Therefore, it is possible that amino acid input regulates both Rag GTPases-mediated localization of mTORC1 and hVps34-PLD1-mediated association of Rheb with mTORC1 to fully activate mTORC1 ( Fig. 2) .
Under many stressful conditions, TORC1 activity is repressed to stop cell growth and to shift cell physiology towards inducing cytoprotective programs (1, 22) . Understanding mechanisms leading to TORC1 inactivation are also important because constitutive activation of mTORC1 is implicated in the development of many diseases (4). In mammals, adenosine monophosphate-activated protein kinase (AMPK) and TSC1/2 inhibit mTORC1 activity under a broad array of stressful conditions including hypoxia, energy depletion and DNA damage. AMPK is activated by increase in the AMP/ATP ratio under conditions such as energy deprivation and hypoxia. Activated AMPK inhibits mTORC1 via two known mechanisms (23) . AMPK directly phosphorylates TSC2 at Ser1387, which results in activation of its GAP activity towards Rheb and this in turn represses mTORC1. In the second mechanism, AMPK directly phosphorylates Raptor at Ser922 and Ser972, which promotes association of Raptor with 14-3-3 protein and inactivation of mTORC1 kinase activity (Fig. 2) . DNA-damaging agents inhibit mTORC1 through activation of AMPK, in which Sestrin1 and Sestrin2 induced by p53 directly bind and activate AMPK without increase in the AMP/ATP ratio (24) . p53 may also repress mTORC1 activity through transcriptionally upregulating negative regulators of mTORC1 including PTEN, AMPK and TSC2 (25, 26) . Furthermore, DNA damage and hypoxia inhibit mTORC1 by inducing the expression of REDD1 protein that activates TSC1/2 by dissociating 14-3-3 protein from TSC2 (27, 28) .
Novel mechanisms of TORC1 regulation under stressful conditions have recently emerged in both yeast and mammals ( Fig. 3 ). Budding yeast (Saccharomyces cerevisiae) lacks TSC1/2, but TORC1 activity is still repressed under various stressed conditions such as heat, oxidation and cell wall damage (29) . Recent studies have uncovered that inactivation of TORC1 under these conditions is at least in part mediated by Rho1 small GTPase (30, 31) . Rho1 (RhoA in mammalian cells) directly binds to TORC1 and thereby inhibits the TORC1 kinase activity both in yeast and in mammalian cells. Furthermore, stress granules, cytoplasmic aggregates composed of stalled translation initiation complexes formed under stressful conditions (32) , play a role in the regulation of TORC1 activity both in yeast and in mammals. Under severe heat stress, yeast TORC1 dissociates from the limiting membrane of the vacuole (the lysosome counterpart in yeast) and is recruited into stress granules (33) . Spatial sequestration of yeast TORC1 into stress granules maintains yeast TORC1 in an inactive state, which promotes cytoprotective effects. In mammalian cells, mTORC1 is also sequestered into oxidative stressand osmotic stress-induced stress granules and inactivated (34) . Further elucidation of new regulatory mechanisms of TORC1 will lead to a comprehensive understanding of complex regulation of TORC1 under various stressful conditions.
Regulation of TORC2 Activity
Less is known about the regulation of TORC2 than about TORC1 regulation. A well-known signal activating mTORC2 is growth factors such as insulin (35) . mTORC2 may also be regulated by amino acids, depending on specific substrates, cellular contexts and/or conditions (3032). Although the mechanism of mTORC2 regulation is poorly defined, ribosome has been reported to be a direct activator of mTORC2 in response to insulin (36) (Fig. 2) .
Insulin promotes binding of the ribosome to mTORC2 and this interaction leads to activation of mTORC2 (36) . Because mTORC1 is a primary regulator of ribosome biogenesis, activation status of mTORC1 may coordinately control mTORC2 activation to achieve appropriate cell growth. Although yeast lacks a growth factor signalling pathway, the requirement of ribosome for activation of TORC2 is likely conserved (36) . Thus, ribosomeTORC2 association may be a key step in activation of TORC2 that is conserved throughout evolution. The localization of TORC2 in both mammalian cells and yeast appears to be on the plasma membrane (or at least on membranous structures) (37) . Interestingly, in endothelial cells, localization of mTORC2 on the plasma membranes is regulated by syndecan-4 in a PKCa-dependent manner, and the localization is required for mTORC2 activation (38) . It will be interesting to determine whether the plasma membrane-associated pool of ribosomes is specifically involved in the activation of TORC2.
In yeast S. cerevisiae, TORC2 is activated by plasma membrane stress, which is encountered during cell growth because of the enlargement of cell surface area (37) . In this step, the PH-domain-containing plasma membrane proteins Slm1 and Slm2 act as upstream regulators of TORC2. Upon stress on the plasma membrane, such as inhibition of sphingolipid biosynthesis or mechanical stretching of plasma membrane, Slm proteins are relocalized away from specialized compartments within the plasma membrane called eisosomes, and then they associate with TORC2. Slm proteins likely play a role to facilitate TORC2 phosphorylation of Ypk1, a downstream effector, by directly recruiting Ypk1 to proximity of TORC2. The activated Ypk1 in turn promotes biosynthesis of sphingolipids, which eventually limits TORC2 activation, thereby building a feedback loop of regulation of sphingolipids homeostasis (37, 39) .
Another upstream regulator of TORC2 is Ryh1 in Schizosaccharomyces pombe (also called fission yeast). Although the stimuli that activates TORC2 in S. pombe is unclear, some studies have indicated that Ryh1, the ortholog of mammalian Rab6 GTPase, directly binds to TORC2 and regulates TORC2 activity (40) . Ryh1 has been implicated in regulation of the vesicle transport between endosomes and the Golgi apparatus; although the function of Ryh1 in TORC2 activation is likely distinct from its role in the control of vesicular trafficking.
TORC1 Downstream Events
TORC1 generally regulates anabolic processes such as protein synthesis and catabolic processes such as autophagy to make an appropriate decision of cell growth in response to environmental cues. The wellcharacterized cellular processes that TORC1 regulates Fig. 3 Stress granule-mediated regulation of TORC1 in yeast. Upon certain stressful conditions (e.g. high temperature), Rho1 is activated, which in turn inhibits TORC1 and releases it from the vacuole. TORC1 is recruited into stress granules and is maintained in an inactive state. Relocalization of TORC1 into stress granules is also conserved in mammals.
Overview of conserved TOR signalling are mRNA translation, ribosome biogenesis, lipid metabolism and autophagy (Fig. 1B) .
mRNA translation
The best-characterized substrates of mTORC1 are 4E-BP1 and p70 ribosomal protein S6 kinase 1 (S6K1), both of which are involved in the regulation of mRNA translation. Very recently, it was reported that inhibition of mTORC1 activity by Torin 1, an ATP-competitive inhibitor, resulted in decrease of translation of almost all mRNAs (99.8% of 4840 transcripts examined) to some extent (median ¼ 60.5%), suggesting the large contribution of mTORC1 in the general control of mRNA translation (41) . 4E-BP1 is an endogenous inhibitor of eIF4E, a translation initiation factor that binds to the 5 0 -cap structure of mRNA, which promotes translation initiation. Phosphorylation of 4E-BP1 by mTORC1 prevents its association with eIF4E, thereby allowing cap-dependent translation initiation. The mRNAs that are most suppressed upon mTORC1 inhibition possess 5 0 -TOP (terminal oligopyrimidine tract), which consists of cytosine at the 5 0 -terminus followed by a stretch of 415 pyrimidines, or 5 0 -TOP-like sequences (41) . How translation of these 5 0 -TOP mRNAs are regulated has been controversial. However, recent studies have clearly demonstrated that translation of the 5 0 -TOP mRNAs is largely controlled by mTORC1mediated phosphorylation of 4E-BP1 (41, 42) . The 5 0 -TOP is mainly found in mRNAs that encode ribosomal proteins and other factors responsible for regulation of protein synthesis. Activation of mTORC1 affects overall mRNA translation not only by regulation of translation initiation through relieving eIF4E from inhibition by 4E-BP1, but also by upregulation of the translation capacity.
Phosphorylation of S6K1 by mTORC1 also promotes mRNA translation through various pathways by phosphorylation of multiple downstream effectors of S6K1 involved in mRNA translation and splicing processes, such as eIF4B, PDCD4, eEF2K and SKAR (43) . Intriguingly, the eukaryotic translation initiation factor eIF3 complex acts as a scaffold for mTORC1 to phosphorylate S6K1 (43, 44) . In the absence of nutrients or growth factors, inactive S6K1 is bound to eIF3. Upon activation of mTORC1 by nutrients or growth factors, mTORC1 is recruited to the eIF3 complex and phosphorylates S6K1. Activated S6K1 dissociates from eIF3, and in turn phosphorylates many downstream effectors as mentioned earlier. It will be interesting to determine how and if the activated mTORC1 on the lysosomal surface binds to either the general or a specific pool of eIF3.
Ribosome biogenesis
Ribosome biogenesis is a fundamental process for maintaining cell growth and proliferation. It is a highly energy-consuming task requiring coordinated regulation of all three RNA polymerases (RNA polymerase I, II and III). TORC1 is known to be involved in processes associated with all three RNA polymerases.
rRNA synthesis by RNA polymerase I requires factors such as transcription initiation factor 1A (TIF-IA), selectivity factor 1 (SL1) and upstream binding factor (UBF), which recruit RNA polymerase I onto rDNA promoters. The mTORC1-S6K1 axis activates TIF-IA and UBF, promoting the association of RNA polymerase I with rDNA promoter and enhances rRNA expression (45) . TORC1 in both yeast and mammals can be recruited to the promoter region of rDNA (46, 47) , indicating that mTORC1 may also regulate rRNA transcription in a more direct way.
Regulation of ribosomal protein (RP) transcription by RNA polymerase II has been elucidated in yeast. Ribosome consists of 79 different RPs, and therefore the coordinated expression and assembly of these RPs are required for efficient production of ribosomes. Yeast TORC1 regulates RP transcription and ribosome biogenesis (Ribi) regulon, the latter of which comprises a set of genes involved in ribosome synthesis and maturation, mostly through the activation of the downstream effector Sch9, the yeast ortholog of S6K1 (48) .
tRNA and 5S RNA are synthesized by RNA polymerase III. TORC1 regulates their transcription through phosphorylation of Maf1, a repressor of RNA polymerase III. In yeast, Maf1 is mainly phosphorylated by Sch9, while it is directly phosphorylated by mTORC1 in mammals (49) . In both systems, Maf1 phosphorylation blocks its nuclear localization, leading to induction of tRNA and 5S RNA expression.
Lipid biosynthesis
Recent studies have revealed that mTORC1 positively regulates lipid biosynthesis mainly through sterol regulatory element-binding protein-1c (SREBP-1c), a master transcription factor regulating gene required for lipids biosynthesis (50) . Insulin stimulates nuclear accumulation of SREBP-1c by promoting processing and maturation of it's membrane-bound inactive precursor in the endoplasmic reticulum (ER), thereby leading to transcriptional activation of lipogenic genes. Although the exact mechanism by which mTORC1 could promote SREBP-1c activation has not been well established, it could occur through multiple pathways: mTORC1 activation increases SREBP-1c expression by an unknown mechanism, and promotes SREBP1 processing and nuclear accumulation, in part, through S6K1 (4, 50) . Moreover, a recent report has demonstrated that mTORC1 phosphorylation of lipin 1, a phosphatidic acid phosphatase, inhibits its translocation into the nucleus, allowing nuclear accumulation of SREBP-1c through an uncharacterized mechanism (51) . A recent study has also suggested that mTORC2 activation in addition to mTORC1 activation is required for promotion of SREBP-1c-mediated lipogenesis (52) .
Autophagy
Autophagy is a major lysosomal degradation process of cytoplasmic components and organelles, which supplies nutrients to cells enabling them to survive under conditions of nutrient deprivation (53) . In both yeast and mammalian cells, TORC1 regulates the initial step of autophagy induction, although the precise regulatory mechanism differs between the two systems. In yeast, TORC1 directly phosphorylates and inhibits Atg13, an initiator of autophagy. TORC1 inhibition under nutrient starvation causes dephosphorylation of Atg13, allowing association of Atg13 with the Ser/Thr kinase Atg1 and the subsequent activation of the Atg13Atg1 kinase complex. The activated Atg13Atg1 complex phosphorylates downstream effectors to promote formation of autophagosomes. In mammalian cells, mTORC1 regulates the UNC-51-like kinases (ULK1) complex, which consists of ULK1, Atg13, Atg101 and a 200-kDa FAK-family interacting protein (FIP200), of these, ULK1 is the mammalian ortholog of Atg1. In the nutrient-rich condition, mTORC1 directly phosphorylates ULK1 and Atg13 through binding with ULK1, and inactivates the ULK1 complex. Upon mTORC1 inhibition, mTORC1 dissociates from the ULK1 complex, and thereby activates ULK1. Activated ULK1 is thought to phosphorylate Atg13 and FIP200, which in turn induces formation of autophagosomes through unknown mechanisms (53) .
TORC2 Downstream Events
mTORC2 phosphorylates several AGC family kinases on their hydrophobic motifs, including Akt, SGK1 and protein kinase C (PKC), through which mTORC2 regulates a variety of cellular processes such as cell survival, proliferation and actin reorganization (Fig. 1B) .
AGC kinase phosphorylation mTORC2 phosphorylates Akt1 at Ser473 within the hydrophobic motif, which is required for its full activation (54) . This phosphorylation appears to occur on the plasma membrane, where mTORC2 resides. Although mTORC2 kinase activity is enhanced in response to growth factors, Akt1 phosphorylation at Ser473 appears to be regulated also through the recruitment of Akt1 to the plasma membrane in response to PI(3,4,5)P 3 production by PI3K. Indeed, hyperactive mTORC2 is unable to maintain Akt1 phosphorylation upon growth factor starvation (55) . Such a local control of Akt1 phosphorylation, i.e. differential phosphorylation of distinct Akt1 fractions in the cells, might affect regulation of downstream effectors. In fact, the need for this Akt1 phosphorylation by mTORC2 differs among the downstream effectors. In mTORC2-deficient cells, where Akt1 Ser473 phosphorylation is completely abolished, FOXO1/3a phosphorylation is impaired, whereas phosphorylation of other downstream effectors such as TSC2 and GSK3b is unaffected (56, 57) .
mTORC2 also phosphorylates Akt1 at Thr450 within the turn motif even in the absence of growth factor. This phosphorylation is constitutive and occurs cotranslationally, which contributes to the folding and stability of Akt1 (58) . mTORC2 phosphorylates and activates SGK1, a kinase involved in regulating sodium transport and cell survival. SGK1 phosphorylation by mTORC2 is specifically mediated by binding of SGK1 to the mTORC2 component mSin1 and has been shown to be required for activation of sodium transport in epithelial kidney cells (59) . The yeast counterparts of SGK1, Ypk1 and Ypk2 are also phosphorylated by TORC2 and are involved in controlling sphingolipid biosynthesis and actin organization (37, 60) .
Actin organization
The link between TORC2 and actin organization was first shown in yeast and later in mammalian cells (61) . Depletion of TORC2 causes defects in actin organization. In S. cerevisiae, although the precise mechanism by which TORC2 regulates actin organization remains to be elucidated, several effectors such as Rho1 GTPase, Ypk2 and Slm1/2 have been shown to be involved in this process (48) . Upon activation, Rho1 binds to Pkc1 kinase, which in turn activates the downstream cascade, leading to actin organization in yeast. TORC2 appears to activate Rho1 through its GEF Rom2 by an unknown mechanism. It is possible that changes in the lipid composition of the plasma membrane through the TORC2-Slm1/2-Ypk1/2 axis primarily affects the ability of Rom2 to bind PI(4,5)P 2 on the plasma membrane, which in turn activates the Rho1-Pkc1 pathway (62) .
In mammals, mTORC2 appears to regulate actin organization by promoting phosphorylation of PKCa and paxillin and by activation of RhoA and Rac1 (4, 35, 61) . Interestingly, Rac1 also binds to mTOR and regulates subcellular localization of mTORC1 and mTORC2 (63), thereby acting both upstream and downstream of mTORC2. It is proposed that Rac1 translocates to the plasma membrane upon growth factor stimulation and recruits mTORC2 and P-Rex1 (a GEF towards Rac1), resulting in local activation of Rac1 and subsequent increase of PI(3,4,5)P 3 synthesis through promotion of PI3K activation (64), leading to both actin organization and Akt activation.
Lipid biosynthesis
As described in TORC1-mediated events, lipid biosynthesis is mainly regulated by mTORC1 in mammalian cells. However, recent studies, especially in yeast, suggest that TORC2 plays an important role in the regulation of sphingolipid biosynthesis, building a feedback loop of sphingolipid biosynthesis and TORC2 activation (37, 39) .
Although mTORC1 regulates lipogenesis in mammalian cells, activation of mTORC1 alone was not sufficient for activation of SREBP-1c and lipogenesis in TSC1 knockout mice (65) . Furthermore, a recent study of liver-specific Rictor knockout mice suggests that mTORC2 appears to positively regulate lipogenesis, at least in part, through Akt1-mediated activation of SREBP-1c (52) . Importantly, SREBP-1c activation and subsequent expression of lipogenic genes are impaired in these mice without affecting mTORC1 activity, suggesting the mTORC2-specific function of lipogenesis. Thus, both mTORC1 and mTORC2 positively activate lipogenesis. Further studies are needed to elucidate the complex metabolic outcomes regulated via TORC1 and TORC2, which will provide valuable data that can be used to develop targeted therapy for obesity and diabetes.
Conclusion
Much progress has been made in the understanding of TOR signalling during the past years, especially regarding amino acid-induced TORC1 activation. However, only a few of the vast array of functions of TOR are known, given that data revealing new links of TOR to unrecognized cellular activities are constantly emerging. Because TOR is involved in essentially all aspects of cellular activities owing to its fundamental ability to sense and respond to nutrients, the regulatory mechanisms of TOR must be tightly controlled by multiple mechanisms while allowing the necessary sharp and robust responses to even subtle or conflicting environmental conditions. Elucidation of the complex molecular mechanisms of TOR signalling through genetic, pharmacological and biochemical studies on various experimental models ranging from yeast to mammals will certainly provide beneficial knowledge. 
